Transmitted drug resistance in nonsubtype B HIV-1 infection. Issue 5 (September 2009)

• Record Type: Journal Article
• Authors: Chan, Philip A; Kantor, Rami
• Is Part Of: HIV therapy. Volume 3:Issue 5(2009)
• Page Start: 447
• Page End: 465
• Publication Date: 2009-09
• Subjects: diversity -- drug resistance -- HIV-1 -- nonsubtype B -- resistance transmission -- transmitted drug resistance -- treatment-naive; HIV (Viruses) -- Treatment -- Periodicals; HIV (Viruses) -- Research -- Periodicals; 616.979206
• DOI: 10.2217/hiv.09.30
• Languages: English
• ISSNs: 1758-4310

Abstract

HIV-1 nonsubtype B variants account for the majority of HIV infections worldwide. Drug resistance in individuals who have never undergone antiretroviral therapy can lead to early failure and limited treatment options and, therefore, is an important concern. Evaluation of reported transmitted drug resistance (TDR) is challenging owing to varying definitions and study designs, and is further complicated by HIV-1 subtype diversity. In this article, we discuss the importance of various mutation lists for TDR definition, summarize TDR in nonsubtype B HIV-1 and highlight TDR reporting and interpreting challenges in the context of HIV-1 diversity. When examined carefully, TDR in HIV-1 non-B protease and reverse transcriptase is still relatively low in most regions. Whether it will increase with time and therapy access, as observed in subtype-B-predominant regions, remains to be determined.